Listen to Gynecologic Oncology

Editor's Choice:  FIGO 2023 staging may result in overtreatment of early-stage endometrial cancer

Editorial: A path to precision in endometrial cancer management: Moving past FIGO 2023

Hosted by: 
David Gaffney, MD, PhD
The University of Utah, Salt Lake City, Utah, United States of America
Featuring: 
Allison Roy, MD
SUNY Upstate Medical University, Syracuse, NY, United States of America
Jessica N. McAlpine
University of British Columbia,  Vancouver, BC, Canada
David Mutch
Washington University School of Medicine, St Louis, MO, United States of America
Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: 2026 update

Editorial: The evolving landscape of personalized perioperative care: A commentary on the 2026 ERAS® Gynecologic oncology guidelines

Hosted by: 
Sean C. Dowdy, MD; Division of Gynecologic Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA
Featuring: 
Gregg Nelson, MD, PhD; Department of Obstetrics & Gynecology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
Richard D. Urman, MD; Department of Anesthesiology, The Ohio State University Wexner Medical Center and College of Medicine, Columbus, OH, USA
Olle Ljungqvist, MD, PhD; Department of Molecular Medicine & Surgery, Karolinska Institutet, Stockholm, Sweden
Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial

Editorial: Hitting the mark—or missing it? The promise and peril of biomarkers in endometrial cancer

Hosted by: 
Amanda Nickles Fader, MD; Johns Hopkins Medicine Baltimore, MD, USA
Featuring: 
Kathleen Moore, MD; Gynecologic Cancer Clinic, Stephenson Cancer Center at the University of Oklahoma Medical Center, Oklahoma City, OK, USA
Ramez N Eskander, MD;  Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, UC San Diego, USA

Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding

Editorial: Tampon-based methylated DNA testing for endometrial cancer: Promising innovation, but prudence before practice
Hosted by: 
Charles N. Landen Jr., MD; University of Virginia Charlottesville, VA, USA
Featuring: 
Jamie N. Bakkum-Gamez, MD; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA
John B. Kisiel, MD; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
Joy M. Davis MD; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review

Moderator:
Ursula A. Matulonis, MD; Dana-Farber Cancer Institute
Speakers:
Bhavana Pothuri, MD; Perlmutter Cancer Center, NYU Langone Health
Róisín E. O’Cearbhaill, MD; Gynecologic Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; Department of Medicine, Weill Cornell Medical College
Yvette Drew, MBBS, PhD; BC Cancer Centre Vancouver and University of British Columbia
Christina Washington, MD; Stephenson Cancer Center, University of Oklahoma

Ursula A. Matulonis, MD, is joined by Bhavana Pothuri, MD, Róisín O’Cearbhaill, MD, Yvette Drew, MBBS, PhD, and Christina Washington, MD, to discuss recent updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors (PARPi) in ovarian cancer. Based on the recent Society of Gynecologic Oncology clinical practice review published in Gynecologic Oncology, the speakers review the evolving role of PARP inhibitors and the clinical implications of updated regulatory approvals.
The panel explores current evidence supporting PARP inhibitor use in ovarian cancer, including considerations for patient selection, biomarker testing, maintenance therapy, and safety considerations. The speakers also discuss how recent changes in FDA indications may affect clinical decision-making and treatment sequencing in practice.
This podcast highlights practical clinical pearls to help guide practitioners in the appropriate integration of PARP inhibitors into the management of ovarian cancer patients.

This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology.
Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net